Radius Recycling, Inc. - RDUS STOCK NEWS

Radius Health reported Q4 2020 net sales of TYMLOS at $60 million, an 8% increase year-over-year, contributing to a full-year revenue of $208 million, up 20% from 2019. New patient starts rose by 26% in Q4 compared to Q3. The company recorded a net loss of $21.4 million in Q4 2020, improving from a loss of $24.7 million in Q4 2019. R&D expenses increased to $36.4 million, driven by RAD011 and abaloparatide programs. Despite a cash balance of approximately $115 million at year-end, Radius reduced its workforce by over 25% to enhance operational efficiency.

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health announced it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on February 25, 2021. The presentation will be accessible via a live webcast on the Company's website, with a replay available for 90 days afterwards.

Radius is focused on developing endocrine therapeutics, with its lead product TYMLOS® approved for treating high-risk postmenopausal women with osteoporosis. The company has additional investigational drugs targeting osteoporosis and hormone-receptor positive breast cancer.

Radius Health (Nasdaq: RDUS) will announce its fourth quarter financial results on February 25, 2021, followed by a conference call at 8:30 a.m. ET. The call will provide insights into the company’s performance and future prospects. Investors can listen to the live audio webcast on the company’s website, and a replay will be available later that day. Radius focuses on innovative endocrine therapeutics, with its lead product TYMLOS (abaloparatide) approved for osteoporosis treatment. The company is also advancing several investigational drugs in its pipeline.

Radius Health reported a 17% increase in new TYMLOS® patients in January 2021, totaling 1,692 new patients compared to prior months. The company highlighted recent publications in the Journal of Bone & Mineral Research and Journal of Clinical Endocrinology & Metabolism that underscore the efficacy and safety of the abaloparatide molecule. Ongoing regulatory activities are on schedule in the U.S., Japan, Canada, and the E.U. Radius is also focused on completing the ATOM study and wearABLe study for further development of TYMLOS.

On January 6, 2021, Radius Health, Inc. (Nasdaq: RDUS) announced that CEO Kelly Martin will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 9:10 a.m. EST. A live webcast can be accessed through the Investors section of Radius' website, with a replay available for 90 days post-presentation.

Radius is a biopharmaceutical company focused on endocrine therapeutics, with its lead product TYMLOS approved for treating high-risk osteoporosis in postmenopausal women. The company is also exploring treatments for men with osteoporosis and hormone-receptor positive breast cancer.

Radius Health has acquired global development rights to RAD011, a synthetic cannabidiol oral solution, for $12.5 million, with up to $60 million in milestone payments. The drug targets Prader-Willi syndrome (PWS), an orphan disease, and has received Orphan Drug and Fast Track Designation from the FDA. The acquisition will be funded through existing operations, minimizing shareholder dilution. Radius expects to initiate a pivotal Phase 2/3 study for PWS in late 2021, with potential top-line data available by 2023. A one-time charge of up to $16 million is expected in Q4 2020 due to the acquisition.

On January 5, 2021, Endo International plc (NASDAQ: ENDP) announced a licensing agreement with Radius Health, Inc. (NASDAQ: RDUS) for the exclusive commercialization of abaloparatide in Canada, through its subsidiary Paladin Labs Inc. Abaloparatide is an investigational treatment for osteoporosis, with Paladin expected to file a New Drug Submission with Health Canada by Q1 2022. The drug is not yet approved in Canada, but Endo aims to address a significant treatment gap for osteoporosis patients.

Radius Health has formed an agreement with Endo Ventures to commercialize and distribute abaloparatide in Canada. This partnership includes an upfront payment and milestone payments totaling around $8 million, plus tiered royalties on net sales. Paladin Labs will manage all commercial activities, targeting a New Drug Submission to Health Canada for TYMLOS® by early 2022. The initiative marks a strategic effort to expand abaloparatide's presence in select ex-U.S. markets, reflecting Radius's commitment to growth in 2021.

Radius Health, Inc. (Nasdaq: RDUS) has appointed Machelle Sanders and Dr. Andrew C. von Eschenbach to its board of directors, filling vacancies left by Jessica Hopfield, Ph.D. and Tony Rosenberg. Sanders brings over 25 years of pharmaceutical experience, having previously led Biogen's operations for its MS franchise. Dr. von Eschenbach, a former FDA commissioner, adds significant expertise in translating science into therapeutics. Chairman Owen Hughes expressed confidence in their contributions to Radius's emerging pipeline as the company refines its focus.